solute carrier family 18 member A3Genealiases: CMS21 · VACHT
Q-omics provides the consensus-scored SLC18A3 profile across patient tissues and cancer cell-line models. SLC18A3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SLC18A3 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SLC18A3 RNA expression shows 8,493 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight CESC, COAD, and ESCA as cancer lineages where SLC18A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC18A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC18A3 survival associations across molecular data types. SLC18A3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC18A3 RNA expression–survival associations across cancer types. High SLC18A3 expression shows unfavorable associations in CESC, LIHC, UCEC, KIRC, LUAD and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for SLC18A3 RNA expression.
This table summarizes SLC18A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC18A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC18A3 shows lower tumor expression in COAD, STAD and BLCA and higher tumor expression in KIRC, THCA and LUSC. The COAD box plot shows higher SLC18A3 RNA expression in normal versus tumor tissue (log2 FC = −0.672, t-test p < 0.001).
This table shows molecular features associated with SLC18A3 in patient tissues and cancer cell lines. In patient samples, SLC18A3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC18A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
